OurCrowd launches $50M medtech fund

OurCrowd, a leading global investment platform and Israel’s most active venture investor, has announced the launch of the OurCrowd Medtech Fund. The $50 million fund will focus exclusively on investing in disruptive medical technologies and therapeutics with the potential to transform global healthcare delivery and patient outcomes.

This is OurCrowd’s first fund dedicated to the rapidly developing medtech market valued globally at $433.7 billion in 2018 and projected to be worth nearly $594.5 billion by 2024.

The OurCrowd Medtech Fund will focus on medical devices, therapeutics, medical robotics and new developments in the medical industry. Current notable OurCrowd medtech investments to date include:

• AlphaTau Medical: new radio therapy for solid cancer tumors
• UPnRIDE: electric wheelchair that enables stable standing and mobility for handicapped individuals
• Insightec: MR-guided focused ultrasound for non-invasive surgery
• MeMed: preventing misuse of antibiotics
• Zebra Medical Vision: Medical imaging insights platform with algorithm-based assistance for radiologists
• Sight Diagnostics: Point of care blood diagnostics utilizing computer vision
• Memic: Robotic arm that extends & improves upon surgeon’s natural movements
• Syqe Medical: World’s first selective-dose pharmaceutical grade medicinal plants inhaler

The fund will be led by managing partners Dr. Morris Laster and Dr. Morry Blumenfeld and will be managed by a team of clinical experts with decades of experience in medical technologies and startup growth.